Riverwater Partners’s Fresenius Medical Care FMS Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$346K Hold
15,306
0.1% 166
2026
Q1
$345K Hold
15,306
0.12% 158
2025
Q4
$365K Hold
15,306
0.14% 157
2025
Q3
$403K Hold
15,306
0.17% 140
2025
Q2
$437K Hold
15,306
0.21% 127
2025
Q1
$381K Sell
15,306
-1,075
-7% -$25.6K 0.2% 123
2024
Q4
$371K Hold
16,381
0.18% 135
2024
Q3
$346K Buy
16,381
+3,736
+30% +$73.5K 0.17% 147
2024
Q2
$241K Hold
12,645
0.18% 161
2024
Q1
$244K Sell
12,645
-155
-1% -$3.07K 0.18% 168
2023
Q4
$267K Hold
12,800
0.21% 156
2023
Q3
$276K Sell
12,800
-780
-6% -$18.9K 0.25% 142
2023
Q2
$325K Buy
13,580
+3,582
+36% +$82.1K 0.29% 115
2023
Q1
$213K Buy
+9,998
New +$191K 0.2% 169
2022
Q3
Sell
-9,998
Closed -$249K 199
2022
Q2
$249K Buy
+9,998
New +$299K 0.25% 146
2022
Q1
Sell
-9,998
Closed -$325K 143
2021
Q4
$325K Buy
+9,998
New +$329K 0.29% 136

Other funds holding FMS

Riverwater Partners's FMS Position: Q2 2026 in Review

Riverwater Partners held its Fresenius Medical Care (FMS) position steady in Q2 2026 at 15,306 shares worth $346K. The position accounts for 0.1% of the portfolio, ranked #166.

Riverwater Partners first reported a position in FMS in Q4 2021 and has held it in 16 quarters since. The position peaked at $437K in Q2 2025. 234 funds tracked by Wall St. Rank hold FMS as of Q2 2026.

  • Riverwater Partners held 15,306 shares of Fresenius Medical Care worth $346K as of Q2 2026.
  • Riverwater Partners left its Fresenius Medical Care share count unchanged in Q2 2026.
  • Fresenius Medical Care made up 0.1% of Riverwater Partners's portfolio in Q2 2026, its #166 holding.
  • Riverwater Partners first reported a position in Fresenius Medical Care in Q4 2021 and has held it in 16 quarters since.
  • Riverwater Partners's Fresenius Medical Care position peaked at $437K in Q2 2025.
  • 234 funds tracked by Wall St. Rank held Fresenius Medical Care as of Q2 2026.

Based on Riverwater Partners's 13F filing for Q2 2026, filed 14 Aug 2026.